Wang Li, Chen Su-Fang, Huang Xi-Wei, Wu Zhi-Yang, Zhang Qing-Mei
Department of Cardiology, Quanzhou Traditional Chinese Medicine Hospital, Quanzhou, Fujian Province, China.
Department of Cardiology, The 910th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Quanzhou, Fujian Province, China.
PLoS One. 2025 Jan 24;20(1):e0317498. doi: 10.1371/journal.pone.0317498. eCollection 2025.
To systematically evaluate the efficacy and safety of creatine phosphate sodium in the treatment of viral myocarditis, and to provide guidance for its clinical treatment.
We conducted a search of The Cochrane Library, PubMed, EMbase, and Web of Science databases to retrieve randomized controlled trials (RCTs) on the use of creatine phosphate sodium (CPS) in the treatment of viral myocarditis. The search was conducted up to April 2024. After screening the literature, extracting data, and evaluating the risk of bias in the included studies, we performed a meta-analysis using RevMan 5.4 and Stata17.0 statistical software.
A total of 104 articles were retrieved, and 9 articles with a combined total of 1,116 patients were ultimately included in the meta-analysis. The results of the meta-analysis indicated that the overall efficacy rate in the phosphocreatine sodium treatment group was higher than that in the control group [RR = 1.22, 95%CI (1.15, 1.28), P<0.00001]. Furthermore, post-treatment levels of cardiac troponin I [MD = 0.1, 95%CI (0.07, 0.13), P<0.00001] and creatine kinase isoenzyme [MD = 9.43, 95%CI (7.04,11 .82), P<0 .00001] in the phosphocreatine treatment group were lower compared to those in the control group; both differences between groups were statistically significant. Additionally, there was no significant difference observed in adverse reaction incidence between the phosphocreatine sodium treatment group and conventional treatment group [RR = 1 .07, 95% CI (0 .68, 1 .67), P = O .77].
Creatine phosphate sodium treatment can significantly improve the therapeutic effect of patients with viral myocarditis, and can reduce the levels of cTnI and CK-MB. Compared with conventional treatment, it has good safety.
系统评价磷酸肌酸钠治疗病毒性心肌炎的疗效和安全性，为其临床治疗提供指导。
检索Cochrane图书馆、PubMed、EMbase和Web of Science数据库，以获取关于使用磷酸肌酸钠（CPS）治疗病毒性心肌炎的随机对照试验（RCT）。检索截至2024年4月。在筛选文献、提取数据并评估纳入研究的偏倚风险后，我们使用RevMan 5.4和Stata17.0统计软件进行了荟萃分析。
共检索到104篇文章，最终9篇文章共1116例患者纳入荟萃分析。荟萃分析结果表明，磷酸肌酸钠治疗组的总有效率高于对照组[RR = 1.22，95%CI（1.15，1.28），P<0.00001]。此外，磷酸肌酸治疗组治疗后心肌肌钙蛋白I水平[MD = 0.1，95%CI（0.07，0.13），P<0.00001]和肌酸激酶同工酶水平[MD = 9.43，95%CI（7.04，11.82），P<0.00001]低于对照组；两组间差异均有统计学意义。此外，磷酸肌酸钠治疗组与传统治疗组不良反应发生率比较，差异无统计学意义[RR = 1.07，95%CI（0.68，1.67），P = 0.77]。
磷酸肌酸钠治疗可显著提高病毒性心肌炎患者的治疗效果，并可降低cTnI和CK-MB水平。与传统治疗相比，其安全性良好。
